Xcenda
AmerisourceBergen

HTA Webinar

Panel Discussion with

Anja Schiel, Norwegian Medicines Agency, Lead, EMA Scientific Working Party, Norway and NL

Jens Grüger, Boston Consulting Group Zurich, Univ. of Washington, ISPOR President-elect, Switzerland and USA

John Doyle, Pfizer and Columbia Univ. USA

Co-moderated by:

Chrissie Fletcher, GSK & Fred Sorenson, Xcenda

AmerisourceBergen

AMCP Academy of Managed Care Pharmacy FOUNDATION

Trends in Health Care: Disruptors and Opportunities

Summary of Findings

AMCP Foundation
October 22, 2018

Pfizer

Xcenda AmerisourceBergen

We're at a Time of Incredible Advancements While Lacking Fundamentals of Delivering Affordable and Accessible Care

Amazing advancements







"We have Star Wars science and Flintstones delivery. Our opportunities are in the space age, but our ability to get people to care they need, it's in the Stone Age."

– Physician

Objective and Approach

Identify significant trends and best practices to assist stakeholders who interact with payers to better adjust to and maximize opportunities for cost-effective, affordable, integrated patient care

Trends scan → **30** trends/ areas of impact

Thought leader working group → **6** key trends + **2** global influencers

Desktop research
>170 sources identified

20 multi-stakeholder
1:1 interviews

Payer survey
N=70

Key Topics Were Defined to Capture the Most Impactful Insights

Affordability and Value	▪ Cost of health care, including prescription drugs ▪ Aggregate spending throughout supply chain
Innovative and Curative Therapies	▪ Precision medicine ▪ Gene therapy ▪ Biosimilars
Industry Consolidation	▪ Consolidation defined is simply bringing together 2 (or more) previously independent entities

Key Topics Were Defined to Capture the Most Impactful Insights (cont'd)

Optimal Health Coverage	▪ Design of health insurance to realize the best value while improving the quality of health care services and employee health
Population Health Management	▪ Management of specific diseases in certain populations to improve outcomes
Expedited Drug Approval	▪ When the FDA deems a drug meets a particular unmet clinical need, it has the flexibility to expedite its review. 4 programs offer this flexibility for drugs meeting different qualifying criteria: priority review, accelerated approval, fast track, and breakthrough therapy

Global Influencers Impact All 6 of the Key Topics

Health IT, AI, and Big Data	▪ Examples may include mining pharmacy and insurance data, using large data sets for treatment plans, and wearables that collect patient information
Social Determinants	▪ Conditions in the environments in which people are born, live, learn, work, play, worship, and age that affect a wide range of health, functioning, and quality-of-life outcomes and risks

Statisticians (who have a clue) to the Rescue!